

Award Number: DAMD17-01-1-0022

TITLE: Identification of Signaling Proteins that Modulate
Androgen Receptor Activity

PRINCIPAL INVESTIGATOR: Zhou Songyang, Ph.D.

CONTRACTING ORGANIZATION: Baylor College of Medicine
One Baylor Plaza, Houston, Texas 77030

REPORT DATE: May 2003

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030902 095

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE May 2003	3. REPORT TYPE AND DATES COVERED Annual (23 Apr 2002 - 22 Apr 2003)	
4. TITLE AND SUBTITLE Identification of Signaling Proteins that Modulate Androgen Receptor Activity			5. FUNDING NUMBERS DAMD17-01-1-0022	
6. AUTHOR(S) Zhou Songyang, PhD.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Baylor College of Medicine One Baylor Plaza, Houston, Texas 77030 E-Mail: Mc131367@bcm.tmc.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) Androgens and the androgen receptor (AR) play a critical role in the development and progression of prostate cancers. The majority of prostate cancers initially respond to endocrine treatment (androgen dependent), but eventually become androgen independent that prove fatal. It appears that a functionally active AR may contribute to the progression of androgen-independent prostate cancers. Understanding the signaling pathways that regulate androgen-dependent and -independent activation of AR mediated transcription would provide valuable information for finding an ultimate cure for this disease. We have proposed to identify the signaling components that regulate AR activity using a novel retrovirus-mediated genetic system, and to understand the mechanism of how the identified factors control AR activity. To this end, we have established and optimized our retrovirus-mediated genetic screen approach. The retroviral vectors to be used have been improved which will allow high-efficiency mutagenesis and ease of manipulation and analysis. We have also made significant progress towards optimizing our screening strategies and establishing a suitable cell line for the genetic screen. With these tools in hand, we are in the process of performing the genome wide genetic screen to identify genes that are important for androgen receptor signaling and study how they may contribute to the progression of prostate cancers.				
14. SUBJECT TERMS Mammalian genetic screen, retrovirus, genome wide, signal transduction pathways, androgen receptor, Transcriptional activation			15. NUMBER OF PAGES 7	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusions.....	7
References.....	7
Appendices.....	

Introduction

Androgens play a critical role in regulating prostate development and the evolution of prostate cancer (1). Androgens exert their biological function by activating gene transcription through the androgen receptor (AR), a member of the steroid nuclear receptor superfamily (2). Initially, endocrine treatment of prostate cancer patients either by inhibition of AR/androgen binding or deprivation of androgens can result in tumor regression. However, most prostate cancer patients relapse as the tumors become androgen independent (1, 3, 4, 5). An important step towards prostate cancer remedies is to understand the signaling pathways that regulate androgen-dependent and -independent activation of AR-mediated transcription. We propose to utilize a genetic system to screen for genes that regulate AR activity in cultured cells through high efficiency mutagenesis using Enhanced Retroviral Mutagens (ERM)(6). The overall objective of this proposal is to understand the molecular machinery that regulates AR transcription in normal and tumor prostate cells. We will first establish a genetic screening method to systematically search for genes that modulate AR activity *in vivo* using the PSA (prostate-specific antigen) enhancer and ARE as a reporter. How the identified genes regulate AR transcription activity and subcellular localization in the context of chromatin will then be investigated.

Body

For Task 1, we have proposed to isolate genes that are involved in regulating the activity of androgen receptor. To accomplish this, we proposed to generate a HeLa-AR cell line that would express luciferase and FKBP-caspase driven by ARE, and to use this cell line for genetic screens using engineered retrovirus mutagens. The rationale is to isolate clones of cells that can escape androgen-dependent caspase-mediated apoptosis as a result of retrovirus mediated mutagenesis. Subsequently, the gene loci that have been mutated to confer androgen independence in these clones can be identified.

To achieve this goal, we have have generated a stable HeLa cell line that expresses the androgen receptor (pCMC-AR). These cells were further engineered to express GFP-NTR (Green fluorescent protein-nitroreductase) (7). NTR allows drug selection against GFP-NTR expression. In the presence of metronidazole (MN), NTR-expressing cells will die. We then went on to test the feasibility of using these cells for the genetic screen. The rationale was that we would sort GFP⁺ and GFP⁻ cells respectively after MN treatment. To our disappointment, it was impossible to isolate GFP⁻ cells after androgen treatment. Androgen stimulated GFP expression should be transient. However, we found that the HeLa-GFP cells remained GFP⁺ long after R1881 treatment.

We reasoned that our failure to isolate GFP⁻ cells made it impossible to use cell death as one of the criteria for isolating mutant clones. We therefore modified our screening strategy. As delineated in Figure 1, we will take advantage of the tetracycline-responsive promoter engineered into the ERM vectors (6). This promoter is turned off in the presence of tetracycline (tet-off).

Briefly, we will sort by FACS GFP^{hi}-AR HeLa cells. These cells are then used for infection with the ERM viruses. Successful ERM integration into the genome may result in lowered GFP expression if the ERM activates a repressor of the AR. We then will sort for GFP^{lo} expressing cells and expand these clones. These GFP^{lo} cells will then be maintained in the presence of tetracycline, which should turn off the tet-off promoter and lead to decreased levels of the

putative repressor. Such decrease will in turn alleviate the repression of GFP expression and results in an increase in GFP levels. Clones that exhibit such a shift in GFP expression (from GFP^{hi} to GFP^{lo}, and then to GFP^{hi}) will be expanded and analyzed to clone the gene targeted by ERM. We are currently in the process of finalizing the conditions for the genetic screen using this strategy.




Figure 1. ERM-mediated genetic screening strategy.

In the mean time, we have also optimized our ERM vectors to be used in the genetic screen. We have modified the epitope tags and promoter regions to improve the mutagenesis efficiency and ease of manipulation. A collection of these constructs are illustrated in Figure 2. Because Task 2 is dependent on Task 1, we expect to make significant and new progress once Task 1 is completed.


Key Research Accomplishments

- Improvement of the ERM genetic screen approach
- Improvement of the cells used for the ERM screen


Reportable Outcomes

In our continued effort to improve genetic screen efficacy and efficiency, we have further improved the retrovirus based genetic screen vectors. These new ERM vectors should provide high efficiency mutagenesis. Furthermore, they should provide easier makers and epitopes for analysis and manipulation. At the same time, we have modified our screening strategies to allow for successful genetic screen.


ERM



ERM-HA/FLAG



ERM-FKBP



ERM-puroSD




Figure 2. Schematic representation of various ERM vectors

Conclusions

In summary, we have further improved our genetic screen approach for high efficiency mutagenesis. Our progress was somewhat hampered due to difficulty in generating a suitable cell line to use for the genetic screen, we have overcome this difficulty by modifying our screening strategies. We are well on our way to starting the genetic screen and obtaining mutant clones. The genes that have been mutated in these clones will then be identified and studied to examine how they may affect the androgen receptor signaling pathway. Such information will prove invaluable in our quest for the cure of prostate cancers.

References

1. **Koivisto, P., M. Kolmer, T. Visakorpi, and O. P. Kallioniemi.** 1998. Androgen receptor gene and hormonal therapy failure of prostate cancer. *Am J Pathol* **152**:1-9.
2. **Trapman, J., P. Klaassen, G. G. Kuiper, J. A. van der Korput, P. W. Faber, H. C. van Rooij, A. Geurts van Kessel, M. M. Voorhorst, E. Mulder, and A. O. Brinkmann.** 1988. Cloning, structure and expression of a cDNA encoding the human androgen receptor. *Biochem Biophys Res Commun* **153**:241-8.
3. **Jenster, G.** 1999. The role of the androgen receptor in the development and progression of prostate cancer. *Semin Oncol* **26**:407-21.
4. **Keller, E. T., W. B. Ershler, and C. Chang.** 1996. The androgen receptor: A mediator of diverse responses. *Front Biosci* **1**:d59-71.
5. **Sadar, M. D., M. Hussain, and N. Bruchovsky.** 1999. Prostate cancer: molecular biology of early progression to androgen independence. *Endocr Relat Cancer* **6**:487-502.
6. **Liu, D., Yang, X., Yang, D., Songyang, Z.** 2000. Genetic screens in mammalian cells using Enhanced Retroviral Mutagens. *Oncogene* **19**:5964-72.
7. **Medico E, Gambarotta G, Gentile A, Comoglio PM, Soriano P.** 2001. A gene trap vector system for identifying transcriptionally responsive genes. *Nat Biotechnol* **19**:579-82.